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reported in the largest study (N  407; p  0.01). In four studies reporting total 
 gastrointestinal (GI) AE data, donepezil was consistently associated with a lower 
incidence of GI AEs compared to rivastigmine, with three of these reporting a lower 
incidence for donepezil compared to galantamine. In the largest study reporting 
total GI AEs (N  5462), the incidence was donepezil 6%, rivastigmine 14%, and 
galantamine 24%. In all studies, low numbers of CNS and cardiovascular AEs 
were recorded, with similar incidences of events found across the different AChEIs. 
CONCLUSIONS: In routine clinical settings, mild to moderate AD patients who 
received donepezil had fewer total and GI AEs versus patients treated with rivastigmine 
or galantamine.
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OBJECTIVES: Research has shown bipolar patients are at greater risk for somatic 
illnesses than the rest of the population. This study assesses the incidence and relative 
risk (RR) of physical comorbid disease among patients with bipolar disorder. 
METHODS: A large US longitudinal claims database and medical episode grouping 
software was used to construct disease speciﬁc episodes of care for the years 2006–
2007. The case population consisted of individuals 65 years with an episode of bipolar 
disorder and at least 12 months of continuous enrollment (CE). The control population 
were year-, age- and sex-matched individuals with no mental health or substance abuse 
episodes and at least 12 months CE. A total of 102,670 cases and 205,340 controls 
were matched for the year 2006; 109,124 cases and 218,248 controls were matched 
in 2007. Treemaps produced by SAS v. 9.1 are used to convey the relative rankings 
of disease incidence and RR of disease as compared to persons without mental health 
disorders. RESULTS: Compared to controls, cases had elevated RR of disease ranging 
from 1.25 (conditions of the female reproductive system) to 3.14 (trauma or iatrogenic 
conditions). Among the speciﬁc trauma and iatrogenic conditions, poisoning, adverse 
drug reactions and injury the RRs at least 2.5 times higher than controls. Cases had 
a RR of 1.69 for endocrine and metabolic diseases (e.g diabetes, hypothyroidism, 
hypoglycemia). Musculoskeletal conditions and ear, nose and throat conditions were 
the most common types of physical comorbidities among both cases and controls, 
however, RR was 1.59 times higher for cases. CONCLUSIONS: Compared to patients 
with no mental health diagnoses, patients with bipolar disorder are at greater risk 
for a wide range of physical comorbidities. Treemaps are a valuable tool for visualizing 
the relative impact of a broad range of diseases across two populations.
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OBJECTIVES: Although efﬁcacy and safety are 2 key issues to be taken into account 
when choosing an antidepressant, many other factors may also inﬂuence treatment 
initiation. The purpose of the study was to examine the impact of comorbidities on 
the initiation of antidepressants: duloxetine (DLX), valenfaxine (VLX), and escitalo-
pram (ECP) versus other SSRIs (OSSRI) in patients with major depressive disorder 
(MDD). METHODS: A total of 44,026 MDD patients from a large commercial 
administrative claims database were classiﬁed as initiators of DLX (n  7,567), VLX 
(n  6,106), ECP (n  10,239), or OSSRI (n  20,114) during the year 2006. Patients 
were classiﬁed on their ﬁrst index medication during the study period. All patients 
had no active prescription of the same medication(s) in the prior 3 months. On the 
basis of ICD-9-CM, 17 systemic disease classes and 21 individual diseases in the prior 
12 months were identiﬁed. RESULTS: Patients receiving DLX were more likely than 
those receiving VLX, ECP, and OSSRI to be female (75.1% vs. 71.5%, 69.7%, 70.5%, 
p  0.001) and aged 46 years or above (62.3% vs. 54.6%, 49.8%, 50.5%, p  0.001). 
Nearly all systemic disease classes and individual pain diseases were most prevalent 
in DLX patients, followed by VLX and ECP patients, with OSSRI patients being the 
least. Most signiﬁcant predicting comorbid diseases (OR  1.40) of DLX initiation 
versus OSSRI were ﬁbromyalgia (OR  1.86), low back pain (OR  1.54), and bipolar 
disorder (OR  1.43) after adjustment for demographics and other comorbidities. 
However, no comorbid diseases with an OR  1.40 were associated with VLX and 
ECP initiation versus OSSRI. CONCLUSIONS: Patients initiating DLX have the most 
comorbid diseases, followed by VLX, ECP, with patients initiating OSSRI having the 
least. Speciﬁcally, the presence of chronic pain diseases and bipolar disorder appear 
to be most signiﬁcant predictors of DLX initiation relative to OSSRI.
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OBJECTIVES: Conduct a systematic review in schizophrenia relapse prevention, using 
the same methodology as the recent National Institute for Clinical Excellence (NICE) 
Schizophrenia Clinical Guideline. METHODS: Systematic review of CENTRAL, 
EMBASE, MEDLINE, for double-blind RCTs with, amisulpride, aripiprazole, olan-
zapine, paliperidone, quetiapine, risperidone, ziprasidone or zotepine, (completed 
November 2008). Relapse and withdrawal data were extracted using individual trial 
deﬁnitions. Mixed treatment comparison using Markov Chain Monte Carlo simula-
tion was conducted using a random effects model to estimate the risk of relapse, 
treatment discontinuation due to either intolerable adverse effects (DAE) or other 
reasons. Summary effect estimates are presented as Odd Ratios [OR] with 95% Cred-
ible Intervals (95%CrI) calculated versus placebo. RESULTS: Literature searching 
returned 488 papers that identiﬁed 18 RCTs that were of sufﬁcient quality to be 
included in the analysis. Relapse analysis reported quetiapine (XR) followed by ris-
peridone and zotepine as most effective: quetiapine (XR) (OR: 0.151, 95%CrI: 0.021, 
0.52), risperidone (OR: 0.168, 95%CrI: 0.035, 0.52), zotepine (OR: 0.17, 95%CrI: 
0.017, 0.69), olanzapine (OR: 0.225, 95%CrI: 0.081, 0.513), haloperidol (OR: 0.314, 
95%CrI: 0.075, 0.89), ziprasidone (OR: 0.315, 95%CrI: 0.079, 0.85), paliperidone 
(OR: 0.362, 95%CrI: 0.058, 1.214), amisulpride (OR: 0.387, 95%CrI: 0.041, 1.497), 
apriprazole (OR: 0.518, 95%CrI: 0.09, 1.702). Amisulpride, olanzapine and ziprasi-
done reported lowest OR for DAE. Amisulpride, quetiapine (XR) and olanzapine 
reported lowest OR for withdrawal due to other reasons, respectively. The model was 
considered a good ﬁt for relapse and discontinuation due other reasons but not for 
DAE. CONCLUSIONS: When NICE’s schizophrenia guideline was in production, 
quetiapine (XR) was not licensed in the UK and therefore excluded from the health 
economic model. However, it is now available and the above analysis suggests that 
treatment with quetiapine (XR) could potentially provide beneﬁt in the management 
of schizophrenia relapse prevention. No ﬁrm conclusions can be made from the 
 analysis DAE.
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OBJECTIVES: The objective of this analysis was to compare efﬁcacy and safety 
of duloxetine with placebo in the treatment of major depressive disorder in 
Poland. METHODS: Comparison was based on a systematic review, carried out 
according to guidelines published by the Cochrane Collaboration and the Agency 
for Health Technology Assessment in Poland. The most important medical databases 
(MEDLINE, EMBASE, CENTRAL) were searched. Two reviewers independently 
had selected trials, assessed their quality and extracted data. For efﬁcacy analysis 
improvements in Hamilton Rating Scale for Depression (HAM-D) and quality of 
life were measured. Percentage of patients responding to treatment (deﬁned as q50% 
improvement in HAM-D) and percentage of patients achieving total remission 
(deﬁned as a7 points HAM-D-17) were also reported. Head-to-head comparisons 
based on randomized controlled trials (RCTs) were performed both for safety and 
efﬁcacy analysis. RESULTS: The results of 14 RCTs were included in the analysis. 
After 7 to 9 weeks of treatment duloxetine allowed better improvement than 
placebo in HAM-D scores (WMD  2.26 [2.94; 1.57]) and in quality of life (WMD 
 3.60 [4.89; 2.31]). Percentage of patients with response to treatment (RB  1.42 
[1.29; 1.56]), NNT  6.95 [5.53; 9.37]), and with total remission (RB  1.45 [1.29; 
1.64]), NNT  8.92 [6.80; 12.93]) was also statistically signiﬁcantly higher for 
duloxetine group. Although risk of adverse events was signiﬁcantly higher in dulox-
etine treated patients (RR  1.19 [1.13; 1.24]; NNH  8.60 [6.75; 11.84]), no differ-
ences in the incidence of serious adverse events were observed (RR  0.95 [0.49; 1.84]). 
Withdrawals due to adverse events were signiﬁcantly more frequent in duloxetine 
group than in placebo group (RR  2.11 [1.61; 2.77], NNH  17.31 [12.87 26.44]). 
CONCLUSIONS: Duloxetine is efﬁcacious drug in the treatment of patients 
with major depressive disorder. Safety proﬁle seems to be acceptable (slightly worse 
than placebo).
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OBJECTIVES: Update a previously published systematic review1 of pharmacological 
treatments for acute mania in bipolar I disorder, to include recent publications, includ-
ing new formulation quetiapine extended release (XR), and remission rates. 
METHODS: Systematic review of CENTRAL, EMBASE, MEDLINE, for randomised, 
controlled trials comparing placebo to: aripiprazole, carbamazepine, divalproex, halo-
peridol, lithium, olanzapine, quetiapine XR, and risperidone as monotherapy, in 
the treatment of acute mania in bipolar I disorder, published before March 2009. 
Trials of combination therapy and patients non-responsive to previous therapy were 
excluded. Data were combined through random effects meta-analyses using Compre-
hensive Meta Analysis. Summary effect estimates were presented as Relative Risk 
(RR) versus placebo and 95% Conﬁdence Interval (95%CI). RESULTS: 408 publica-
tions were identiﬁed and overall 19 trials from 18 papers were included in the analysis. 
The results for remission reported that risperidone followed by quetiapine XR were 
the most effective antipsychotics: risperidone (RR:1.87, 95%CI:1.22–2.85), quetiap-
ine XR (RR:1.46, 95%CI:1.07–2.01), olanzapine (RR:1.39, 95%CI:1.08–1.79), 
